7: Angiogenesis (30.01.2020) Flashcards

1
Q

What is angiogenesis?

A
  • Angiogenesis is the formation of neo-vessels from pre-existing blood vessels
  • cascade of events that starts at the endothelial cells, starts in small BVs, starts in response to hypoxia (release of angiogenesis promoting factors e.g. VEGF)
  • The angiogenic process is regulated by a wide array of growth factors and signalling pathways
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Where is angiogenesis seen physiologically and pathologically?

A

Physiology

  • Development
  • Menstrual cycle
  • Wound healing

Pathology

  • Cancer
  • Chronic inflammatory diseases
  • Retinopathies
  • Ischemic diseases
  • Vascular malformations

Not all BVs are the same, the microenvironements are different.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the different ways to make a blood vessel>

A
  • Vasculogenesis (bone marrow progenitor cell)
  • Angiogenesis (sprouting)
  • Arteriogenesis (collateral growth; e.g. in occlusion of a large vessel)

=> angiogenesis is not the only way to make new blood vessels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Inhibitors of angiogenesis

A

Inhibitors:

  • Extracellular Matrix:
    • Thrombospondin-1
    • Angiostatin
    • Endostatin
  • Soluble factors:
    • sVEGF-R
    • IL-10
    • IL-12
    • TNF-a
  • Cell surface receptors:
    • avb3
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Activators of angiogenesis

A

Activators:

  • Growth factors:
    • VEGF family
    • FGF family
    • TGF b
    • PDGF
  • Soluble factors:
    • IL-6
    • Factor XIII
    • TNF-a
  • Cell surface receptors:
    • avb3
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Factors for maturation and integrity in angiogenesis

A
Maturation and Integrity:
VE-Cadherin (Junctions)
Angiopoietin/Tie2
Notch pathway
ERG pathway
Platelets!!
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How is angiogenesis regulated?

A
  • A large number of molecules can influence Angiogenesis
  • Some molecules are essential (i.e. VEGF), other are required for modulation (i.e. VWF)
  • Many are best known for other functions (i.e. TNF-a, VWF)
  • Some have been reported to have both pro- and anti-angiogenic effects
  • Pathways may act in a tissue and stimulus-specific manner
  • growth factors play a key role in the regulation of angiogenesis
  • many signalling pathways

BALANCE between activators and inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the steps of sprouting angiogenesis?

A
  1. tip/stalk cell selection;
  2. tip cell navigation and stalk cell proliferation;
  3. branching coordination;
  4. stalk elongation, tip cell fusion, and lumen formation;
  5. perfusion and vessel maturation.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How does hypoxia trigger angiogenesis?

A

In the presence of oxygen:

  • HIF is bound to pVHL via hydroxyproline (HIF is inhibited by this binding)
  • HIF alpha is destroyed
  • > HIF is continuously produced and removed

In the absence of oxygen

  • pVHL is removed (oxygen take HIF away)
  • free HIF alpha
  • binds to HIF-beta and DNA
  • transcription and translation of:
    • VEGF
    • PDGF
    • EPO
    • TGF-alpha
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

HIF and pVHL

A

HIF: hypoxia-inducible transcription factor, controls regulation of gene expression by oxygen

pVHL: Von Hippel–Lindau tumor suppressor gene, controls levels of HIF

=> important in the angiogenesis response to hypoxia!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Vascular Endothelial Growth Factor (VEGF) and its receptors

A
  • Family of 5 members: VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental growth factor (PlGF)
  • Three tyrosine kinase receptors: VEGF receptor (VEGFR)-1, VEGFR-2, and VEGFR-3; and co-receptors neuropilin (Nrp1 and Nrp2)
  • VEGFR-2 is the major mediator of VEGF-dependent angiogenesis, activating signalling pathways that regulate endothelial cell migration, survival, proliferation.
  • VEGFR2 and VEGFA are supposed to be the main drivers of angiogenesis.
  • when VEGF binds to a cell, this cell beomes a tip cell
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Tip cell selection

A
  • In sprouting angiogenesis, specialised endothelial tip cells lead the outgrowth of blood-vessel sprouts towards gradients of VEGF
  • tip cell selection is based on NOTCH signalling between adjacent endothelial cells at the angiogenic front.
  • After stimulation with angiogenic factors, the quiescent vessel dilates and an endothelial cell tip cell is selected (DLL4 and JAGGED1) to ensure branch formation.
  • Tip-cell formation requires degradation of the basement membrane, pericyte detachment and loosening of endothelial cell junctions.
  • Increased permeability permits extravasation of plasma proteins (such as fibrinogen and fibronectin) to deposit a provisional matrix layer, and proteases remodel pre-existing interstitial matrix, all enabling cell migration.
  • For simplicity, only the basement membrane between endothelial cells and pericytes is depicted, but in reality, both pericytes and endothelial cells are embedded in this basement membrane.
  • Notch R is on the stalk cell and is activated by tip cell in angiogenesis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Canonical Notch signalling pathway

A
  • notch-R has an ec, tm and ic domain
  • binding of ligand (delta/jagged) to notch receptor causes cleavage of ic domain (NICD)
  • > translocates to the nucleus and and binds to the TF RBP-J

Summary: activation of the notch R by a ligand causes translocation of the ic-domain(NICD) to the nucleus and binds to TF RBP-J

  • Notch receptors are found important in many growth functions, e.g. embryogenesis as well as CNS development, CV development+angiogenesis.
  • in angiogenesis the notch-R is on the stalk cell and is activated by the tip cell binding via a ligand (jagged/delta)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Dll4

A
  • delta like ligand 4

- transmembrane ligand for the notch family of receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Selection of Tip cells - VEGF and DLL4 signalling

A
  1. In stable blood vessels, Dll4 and Notch signalling maintain quiescence: the signalling is thought to be balanced in endothelial cells (until presumptive tip cells eventually increase Dll4 expression in response to VEGF signaling)
  2. VEGF activation increases expression of Dll4
  3. Dll4 drives Notch signalling, which inhibits expression of VEGFR2 in the adjacent cell.
  4. Dll4-expressing tip cells acquire a motile, invasive and sprouting phenotype
  5. Adjaucent cells (Stalk cells) form the base of the emerging sprout, proliferate to support sprout elongation.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Sprout outgrowth and guidance

A
  1. Tip cells navigate in response to guidance signals (such as semaphorins and ephrins) and adhere to the extracellular matrix (mediated by integrins) to migrate.
  2. Stalk cells behind the tip cell proliferate, elongate and form a lumen, and sprouts fuse to establish a perfused neovessel.
  3. Proliferating stalk cells attract pericytes and deposit basement membranes to become stabilized.
  4. Recruited myeloid cells such as tumour-associated macrophages (TAMs) and TIE-2-expressing monocytes (TEMs) can produce pro-angiogenic factors or proteolytically liberate angiogenic growth factors from the ECM.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

How do macrophages participate in vessel anastomosis?

A
  • Macrophages play a significant role in both physiological and pathological angiogenesis
  • Macrophages carve out tunnels in the extra cellular matrix (ECM), providing avenues for capillary infiltration
  • Tissue-resident macrophages can be associated with angiogenic tip cells during anastomosis
18
Q

What is the role of platelets in angiogenesis?

A

Regulate angiogenesis -> both pro and anti (they are likely to be modulators)

19
Q

Stabilisation and quiescence of newly formed BVs

A
  • After fusion of neighbouring branches, lumen formation allows perfusion of the neovessel, which resumes quiescence by promoting a phalanx phenotype, re-establishment of junctions, deposition of basement membrane, maturation of pericytes and production of vascular maintenance signals.
  • Other factors promote transendothelial lipid transport.
  • One of the most important things to do is to form junctions.
20
Q

Tight Junctions and Adherens Junctions in Endothelial Cells

A
  • Constitutively expressed at junctions
  • Homophilic interaction mediates adhesion between endothelial cells and intracellular signalling
  • Controls contact inhibition of cell growth (e.g. ability to grow in one layer)
  • Promotes survival of EC
  • VE-cadherin is important here
21
Q

What is the role of pericytes in angiogenesis?

A
  • pericytes/mural cells help stabilise neovessles
  • Pericytes don’t cover all the vasculature (just parts, form a meshwork around it)
  • Produce a lot of chemicals
  • E.g. angiopoietin/tie 2 system -> almost exclusive to endothelium -> pericytes release angiopoietin and stalk cells have TIE2 on their membrane -> increased Dll4…
22
Q

the Angiopoietin-Tie2 ligand-receptor system

A
  • > controls stability
  • Ang-1 is an agonistic and Ang-2 is accompetitively antagonistic ligand of the Tie2 receptor
  • Ang-1 binding to Tie2 promotes vessel stability and inhibits inflammatory gene expression q
  • Ang-2 antagonises Ang-1 signalling, promotes vascular instability and VEGF-dependent angiogenesis

VEGF is essential for driving it. This pathway modulates it.

23
Q

When are Ang-2 plasma levels raised?

A

congestive heart failure
Sepsis
Chronic Kidney Disease

24
Q

Summary of sprouting angiogenesis

A
  1. initiation
  2. selection
  3. tip-cell navigation
  4. stalk elongation
  5. fusion
  6. perfusion and elongation
  7. maturation and stabilisation
  8. quiescence
25
Q

Nutrient supply of tumours

A
  • Tumors less than 1 mm3 receive oxygen and nutrients by diffusion from host vasculature.
  • Larger tumors require new vessel network. Tumor secretes angiogenic factors that stimulate migration, proliferation, and neovessel formation by endothelial cells in adjacent established vessels.
  • Newly vascularized tumor no longer relies solely on diffusion from host vasculature, facilitating progressive growth.
26
Q

The angiogenic switch

A
  • The angiogenic switch is a discrete step in tumour development that can occur at different stages in the tumour-progression pathway, depending on the nature of the tumour and its microenvironment
  • most tumours start growing in avascular nodules
  • until they reach a steady-state level of proliferating and apoptosing cells.
  • The initiation of angiogenesis, or the ‘angiogenic switch’, has to occur to ensure exponential tumour growth.
  • The switch begins with perivascular detachment and vessel dilation (b), followed by angiogenic sprouting (c), new vessel formation and maturation, and the recruitment of perivascular cells (d).
  • Blood-vessel formation will continue as long as the tumour grows, and the blood vessels specifically feed hypoxic and necrotic areas of the tumour to provide it with essential nutrients and oxygen (e).
27
Q

How are tumour BVs different from normal BVs?

A
  • irregularly shaped, dilated, tortuous, may have dead ends
  • not organized into definitive venules, arterioles and capillaries
  • leaky and haemorrhagic, partly due to the overproduction of VEGF
  • perivascular cells often become loosely associated
    some tumours may recruit endothelial progenitor cells from the bone marrow (controversial!)
28
Q

How are pathways in tumours different?

A
  • different pathways are relevant so you can’t deal with the angiogenesis there like with normal vasculature.
  • Cancer-associated fibroblasts (CAFs) secrete extracellular matrix; pro-angiogenic growth factors, (VEGFA; FGF2; CXCL12; PDGFC) -> modulate angiogenesis
  • Pericytes are loosely associated with with tumour-associated blood vessels (TABVs), and this favours chronic leakage in tumours. This is enhanced by angiopoietin 2 (ANGPT2) -> they don’t function properly
  • Platelets release pro-angiogenic mediators and proteases that support the proliferation and activation of CAFs, such as PDGFB and TGFβ; tumours often have haemorrhages because their BVs are leaky.
29
Q

What is the role of tumours in platelet angiogenesis?

A
  • Link between cancer progression and thrombocytosis
  • Activated platelets are a source of:
    • pro-angiogenic factors: VEGFA, platelet-derived growth factors (PDGFs), FGF2
    • angiostatic molecules: thrombospondin 1, plasminogen activator inhibitor 1 (PAI1), endostatin
  • Tumours cause platelet activation, aggregation and degranulation
  • Disrupting platelet function does not obviously impair tumour angiogenesis, however the overall outcome of platelet activation in tumours appears to be pro-angiogenic
30
Q

Therapeutic strategies to inhibit VEGF signalling

A
  • ABs that block VEGF (Bevacizumab/avastin; Aflibercept)
  • VEGFR kinase inhibitors
  • If you block part of the VEGF pathwat you can block angiogenesis.
31
Q

Avastin

A
  • Anti-VEGF humanised MAb
  • 2004: Avastin is FDA approved for the treatment of advanced colorectal cancer
  • now also for other cancers e.g. cervical, glioblastoma, non sc-lung cancer
    = bevacizumab
32
Q

Avastin therapy for cancer

A
  • side effects and limited efficacy
  • No overall survival advantage over chemo alone
  • No QoL or survival advantage
  • In some cases benefits are transitory, followed by a restoration of tumour growth and progression
  • In other cases there is no objective benefit

SE:

  • GI perforation
  • Hypertension
  • Proteinuria
  • Venous thrombosis
  • Haemorrage
  • Wound healing complications

Without VEGF endothelial cells are not very happy.

33
Q

Potential resistance mechanisms to anti-VEGF therapy in cancer

A
  1. VEGF inhibition aggravates hypoxia increasing tumour’s production of other angiogenic factors or increases tumour invasiveness other pathways, and factors still promote angiogenesis)
  2. Tumours vessels maybe less sensitive to VEGF inhibition due to vessel lining by tumour cells or endothelial cells derived from tumours
  3. Tumour cells that recruit pericytes maybe less responsive to VEGF therapy
34
Q

Vasculogenic mimicry

A

Tumor cell vasculogenic mimicry (VM), also known as vascular mimicry, describes the plasticity of aggressive cancer cells forming de novo vascular networks and is associated with the malignant phenotype and poor clinical outcome.

  • tumours organise themselves to form vessel-like channels
  • vessles hook up with channels within the tumour mass
    = tumours pretend to be BVs
35
Q

Anti-angiogenic therapies

A

Anti-angiogenic therapy which normalises vasculature

  • reduces hypoxia
  • Increase efficacy of conventional therapies

Sustained/Aggressive Anti-angiogenic therapy
- May damage healthy vasculature leading to loss of vessels, creating vasculature resistant to
further treatment and inadequate for delivery of oxygen/drugs

-> your aim has to be to normalise the vasculature, It is not very easy.

36
Q

Ideas on the future of angiogenesis therapy in cancer

A
  • Anti-angiogenic therapy in combination with other anti-cancer therapies
  • Resistance: combinatorial strategies involving angiogenesis inhibition & drugs targeting resistance mechanisms
  • Novel non-VEGF targets – novel molecular mechanism
37
Q

RNAseq

A
  • RNA-seq allows you to study all the genes made in the cell.
  • Single cell RNA-Seq:
    • Very complex bioinformatics
    • You can get the profile of expression of genes in different parts of the body.

Studies found:
- New possible targets in lung cancer -> Different types of endothelial cells identified.

38
Q

Anti-angiogenic therapy in other diseases

A
  • Retina vascularization (diabetic retinopathy, wet AMD)
39
Q

Age-related macular degeneration (AMD)

A
  • Abnormal growth of choroidal blood vessels
  • “Leaky” vessels cause oedema
  • Visual impairment
  • No cure for this
  • Intraocular VEGF injection (off label at first)
  • Revolutionary, new way of treating it.
  • very expensive
40
Q

Organ-on-a-chip / tumour-on-a-chip

A
  • new in-vitro models
  • Develp a microphysiological system that incorporates human cells in a 3D extracellular matrix (ECM), supported by perfused human microvessels
  • e.g. in drug screening
41
Q

How to find better therapeutic strategies to inhibit angiogenesis in cancer?

A

Challenge:

  • Tumours are complex three-dimensional (3D) structures with their own unique microenvironments
  • We lack good in vitro models - our understanding of tumour behaviour in a complex 3D environment is limited and drug screens are often misleading.
  • Studies are performed on cell lines growing as two-dimensional (2D) monolayers, which do not mimic the complex interplay between tumour cells and their extracellular environment
  • The phenotype of tumour cells when cultured in 2D vs 3D is different
  • reduces the amount of work done on animals.

Crucially, tumors receive nutrients and therapeutics through the vasculature, which is not included in any in vitro tumor models.

=> tumour-on-a-chip